Literature DB >> 25910438

Electrospun polycaprolactone nanofibers as a potential oromucosal delivery system for poorly water-soluble drugs.

Tanja Potrč1, Saša Baumgartner1, Robert Roškar1, Odon Planinšek1, Zoran Lavrič1, Julijana Kristl1, Petra Kocbek2.   

Abstract

The number of poorly water-soluble drug candidates is rapidly increasing; this represents a major challenge for the pharmaceutical industry. As a consequence, novel formulation approaches are required. Furthermore, if such a drug candidate is intended for the therapy of a specific group of the population, such as geriatric or pediatric, the formulation challenge is even greater, with the need to produce a dosage form that is acceptable for specific patients. Therefore, the goal of our study was to explore electrospun polycaprolactone (PCL) nanofibers as a novel nanodelivery system adopted for the oromucosal administration of poorly water-soluble drugs. The nanofibers were evaluated in comparison with polymer films loaded with ibuprofen or carvedilol as the model drugs. Scanning electron microscopy revealed that the amount of incorporated drug affects the diameter and the morphology of the nanofibers. The average fiber diameter increased with a higher drug loading, whereas the morphology of the nanofibers was noticeably changed in the case of nanofibers with 50% and 60% ibuprofen. The incorporation of drugs into the electrospun PCL nanofibers was observed to reduce their crystallinity. Based on the morphology of the nanofibers and the films, and the differential scanning calorimetry results obtained in this study, it can be assumed that the drugs incorporated into the nanofibers were partially molecularly dispersed in the PCL matrix and partially in the form of dispersed nanocrystals. The incorporation of both model drugs into the PCL nanofibers significantly improved their dissolution rates. The PCL nanofibers released almost 100% of the incorporated ibuprofen in 4h, whereas only up to 77% of the incorporated carvedilol was released during the same time period, indicating the influence of the drug's properties, such as molecular weight and solubility, on its release from the PCL matrix. The obtained results clearly demonstrated the advantages of the new nanodelivery system compared to the drug-loaded polymer films that were used as the reference formulation. As a result, electrospinning was shown to be a very promising nanotechnology-based approach to the formulation of poorly water-soluble drugs in order to enhance their dissolution. In addition, the great potential of the produced drug-loaded PCL nanofiber mats for subsequent formulation as oromucosal drug delivery systems for children and the elderly was confirmed.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Electrospinning; Nanofibers; Oromucosal drug delivery; Polycaprolactone; Poorly soluble drugs

Mesh:

Substances:

Year:  2015        PMID: 25910438     DOI: 10.1016/j.ejps.2015.04.004

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  15 in total

Review 1.  Advancement of Nanofibrous Mats and Common Useful Drug Delivery Applications.

Authors:  Hamza Abu Owida; Jamal I Al-Nabulsi; Feras Alnaimat; Ashraf Al Sharah; Muhammad Al-Ayyad; Nidal M Turab; Mustafa Abdullah
Journal:  Adv Pharmacol Pharm Sci       Date:  2022-04-19

2.  Cilostazol-Loaded Poly(ε-Caprolactone) Electrospun Drug Delivery System for Cardiovascular Applications.

Authors:  Marek Rychter; Anna Baranowska-Korczyc; Bartłomiej Milanowski; Marcin Jarek; Barbara M Maciejewska; Emerson L Coy; Janina Lulek
Journal:  Pharm Res       Date:  2018-01-16       Impact factor: 4.200

3.  Ketoprofen-loaded Eudragit electrospun nanofibers for the treatment of oral mucositis.

Authors:  Rana Ihab Reda; Ming Ming Wen; Amal Hassan El-Kamel
Journal:  Int J Nanomedicine       Date:  2017-03-27

4.  Fast Dissolving Electrospun Nanofibers Fabricated from Jelly Fig Polysaccharide/Pullulan for Drug Delivery Applications.

Authors:  Thangavel Ponrasu; Bei-Hsin Chen; Tzung-Han Chou; Jia-Jiuan Wu; Yu-Shen Cheng
Journal:  Polymers (Basel)       Date:  2021-01-12       Impact factor: 4.329

Review 5.  Biosensors for the Detection of Bacterial and Viral Clinical Pathogens.

Authors:  Luis Castillo-Henríquez; Mariana Brenes-Acuña; Arianna Castro-Rojas; Rolando Cordero-Salmerón; Mary Lopretti-Correa; José Roberto Vega-Baudrit
Journal:  Sensors (Basel)       Date:  2020-12-04       Impact factor: 3.576

6.  Preparation of a Composite Scaffold from Polycaprolactone and Hydroxyapatite Particles by Means of Alternating Current Electrospinning.

Authors:  Radek Jirkovec; Pavel Holec; Sarka Hauzerova; Alzbeta Samkova; Tomas Kalous; Jiri Chvojka
Journal:  ACS Omega       Date:  2021-03-23

7.  Multilayer Alginate-Polycaprolactone Electrospun Membranes as Skin Wound Patches with Drug Delivery Abilities.

Authors:  Andrea Dodero; Marina Alloisio; Maila Castellano; Silvia Vicini
Journal:  ACS Appl Mater Interfaces       Date:  2020-07-02       Impact factor: 9.229

8.  Development of an Electrospun Patch Platform Technology for the Delivery of Carvedilol in the Oral Mucosa.

Authors:  Maria Pardo-Figuerez; Jorge Teno; Alvaro Lafraya; Cristina Prieto; Jose Maria Lagaron
Journal:  Nanomaterials (Basel)       Date:  2022-01-27       Impact factor: 5.076

9.  Synthesis of a Novel Electrospun Polycaprolactone Scaffold Functionalized with Ibuprofen for Periodontal Regeneration: An In Vitro andIn Vivo Study.

Authors:  Fareeha Batool; David-Nicolas Morand; Lionel Thomas; Isaac Maximiliano Bugueno; Javier Aragon; Silvia Irusta; Laetitia Keller; Nadia Benkirane-Jessel; Henri Tenenbaum; Olivier Huck
Journal:  Materials (Basel)       Date:  2018-04-10       Impact factor: 3.623

10.  Fabrication of tri-layered electrospun polycaprolactone mats with improved sustained drug release profile.

Authors:  S Manjunath Kamath; K Sridhar; D Jaison; V Gopinath; B K Mohamed Ibrahim; Nilkantha Gupta; A Sundaram; P Sivaperumal; S Padmapriya; S Shantanu Patil
Journal:  Sci Rep       Date:  2020-10-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.